SEC Form 4 · accession 0000899243-17-027611
MEDICINES CO /DE · MDCO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander J Denner
Director
Period of report
Nov 29, 2017
Accepted (ET)
Nov 30, 2017 · 7:30 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113481
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Nov 29, 2017 | P | 170,000 | $30.03 | A | 1,922,000 | I | See Footnotes |
| Common Stock | holding | — | — | — | 6,663 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On November 29, 2017, funds managed by Sarissa Capital Management LP (such funds, the "Sarissa Funds") purchased an aggregate of 170,000 shares of common stock of The Medicines Company. All of the shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by the Sarissa Funds.
- F2Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and the managing member of the general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.